PROF · Profound Medical Corp.
$6.63
-0.04 (-0.60%)
At close · Aug 14
Market Cap
$242.21M
Shares
36.53M
Profound Medical Corp. Earnings Call Transcripts
Every quarterly earnings call for Profound Medical Corp. (PROF) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$1.44M
−$6.58M
'24 Q1
24-03-31
·
$2.23M
−$6.92M
'24 Q2
24-06-30
·
$2.83M
−$9.37M
'24 Q3
24-09-30
·
$4.18M
−$4.95M
'24 Q4
25-03-07
▲82.1%
$2.62M
−$10.72M
'25 Q1
25-05-08
▼1%
$2.21M
−$15.70M
'25 Q2
25-08-14
▲86.8%
$5.29M
−$7.98M
'25 Q3
25-10-07
▲43.1%
$5.98M
−$8.17M
'25 Q4
26-03-05
▲103.6%
$5.34M
−$7.05M
'26 Q1
26-05-07
LATEST
▲12.3%
$2.48M
−$9.54M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Earnings conference call (announced in 8-K)
Revenue
$2.48M
▲ 12.3% YoY Diluted EPS
$-0.26
Gross margin
78.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Profound Medical Corp. Q1 FY2026 Earnings Call
Revenue
$5.34M
▲ 103.6% YoY Diluted EPS
$0.19
▼ 47.2% YoY Gross margin
71.8%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Profound Medical Corp. Q4 FY2025 Earnings Call
Confident tone
CAPTAIN trial and clinical evidence
Revenue growth and financials
Installed base growth and utilization targets
Revenue
$5.98M*
▲ 43.1% YoY Gross margin
66.8%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-07
Profound Medical Corp. Q3 FY2025 Earnings Call
Confident tone
TULSA-AI Volume Reduction software launch
BPH market expansion
Revenue growth and profitability trajectory
Revenue
$5.29M
▲ 86.8% YoY Diluted EPS
$0.26
▼ 31.6% YoY Gross margin
74.3%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Profound Medical Corp. Q2 FY2025 Earnings Call
Positive tone
Software upgrade / procedure time
CAPTAIN trial milestones
Sales pipeline and funnel
Revenue
$2.21M
▼ 1% YoY Diluted EPS
$-0.52
▼ 285.7% YoY Gross margin
73.2%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Profound Medical Corp. Q1 FY2025 Earnings Call
Confident tone
TULSA-PRO clinical differentiation and CAPTAIN trial
TULSA+ bundled offering with MRI partners
Pipeline of cancer centers and adoption cycle
Revenue
$2.62M
▲ 82.1% YoY Diluted EPS
$0.36
▲ 33.3% YoY Gross margin
70.7%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2025-04-28
Analyst Day 2025
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-03-07
Profound Medical Corp. Q4 FY2024 Earnings Call
Confident tone
TULSA-PRO technology and precision
Commercial organization and capital sales model
Reimbursement and Medicare payments
Revenue
$4.18M*
Gross margin
70.9%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Profound Medical Corp. Q3 FY2024 Earnings Call
Confident tone
TULSA procedure and clinical flexibility
Reimbursement and CPT Category 1 codes
TULSA Plus and Siemens partnership
Revenue
$2.83M
Diluted EPS
$0.38
Gross margin
63.1%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Profound Medical Corp. Q2 FY2024 Earnings Call
Positive tone
Real-world TULSA utilization
Reimbursement and CPT codes
Procedure throughput and economics
Revenue
$2.23M
Diluted EPS
$0.28
Gross margin
63.6%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Profound Medical Corp. Q1 FY2024 Earnings Call
Confident tone
Recurring revenue and utilization growth
Indication breadth and patient spectrum
Reimbursement and CMS pricing
Revenue
$1.44M
Diluted EPS
$0.27
Gross margin
60.2%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Profound Medical Corp. Q4 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Profound Medical Corp. Q3 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Profound Medical Corp. Q2 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Profound Medical Corp. Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Profound Medical Corp. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Profound Medical Corp. Q3 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Profound Medical Corp. Q2 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Profound Medical Corp. Q1 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Profound Medical Corp. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Profound Medical Corp. Q3 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Profound Medical Corp. Q2 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Profound Medical Corp. Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Profound Medical Corp. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Profound Medical Corp. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Profound Medical Corp. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Profound Medical Corp. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts
CIK
1628808
CUSIP
74319B502
13F (30d)
56 filings
56 filers
Visit website
Investor relations